Presentation is loading. Please wait.

Presentation is loading. Please wait.

What is a QALY?. QALY’s Person’s length of life weighted by a valuation of their health-related quality of life.  Quantity (T)  Quality (U) Equation:

Published byCandice Pearson Modified over 9 years ago

Similar presentations

Presentation on theme: "What is a QALY?. QALY’s Person’s length of life weighted by a valuation of their health-related quality of life.  Quantity (T)  Quality (U) Equation:"— Presentation transcript:

1 What is a QALY?

2 QALY’s Person’s length of life weighted by a valuation of their health-related quality of life.  Quantity (T)  Quality (U) Equation: QALY= U x T 01

3 EQ-5D TEST

4 QALY= U x T Intervention A is the best alternative, because it gets a higher value of QALYs.

5 Cost outcomes analysis Cost- Effectiveness Cost-Utility QALY Cost-Benefit Cost- Minimization QALYs are the unit of effectiveness of the cost-utility analysis.

6 QALY disadvantages Is needed the intervention of an expert. The test is not equal for all population. Outcomes are not reliable. Only for chronic diseases. Previous explanation.

Download ppt "What is a QALY?. QALY’s Person’s length of life weighted by a valuation of their health-related quality of life.  Quantity (T)  Quality (U) Equation:"

Similar presentations

Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.

Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.
Market Equilibrium Market equilibrium is the condition that exists when quantity supplied and quantity demanded are equal. At equilibrium, there is no.

Market Equilibrium Market equilibrium is the condition that exists when quantity supplied and quantity demanded are equal. At equilibrium, there is no.
Disability Adjusted Life Years Possibilities and Problems Trude M. Arnesen, Ole Frithjof Norheim.

Disability Adjusted Life Years Possibilities and Problems Trude M. Arnesen, Ole Frithjof Norheim.
A Review and Meta- Analysis of Utility Values for Lung Cancer Julie Migrin ASPH Environmental Health Fellow at the U.S. EPA.

A Review and Meta- Analysis of Utility Values for Lung Cancer Julie Migrin ASPH Environmental Health Fellow at the U.S. EPA.
Equations and Their Solutions

Equations and Their Solutions
HERU is supported by the Chief Scientist Office of the Scottish Government Health Directorates and the University of Aberdeen. The author accepts full.

HERU is supported by the Chief Scientist Office of the Scottish Government Health Directorates and the University of Aberdeen. The author accepts full.
Overview of the day 1015-1100Introduction to Health Economics 1100-1200Introduction to Economic Evaluations 1200-1300LUNCH 1300-1400Appraising Economic.

Overview of the day Introduction to Health Economics Introduction to Economic Evaluations LUNCH Appraising Economic.
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.

1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
Jeff Beard Lisa Helma David Parrish Start Presentation.

Jeff Beard Lisa Helma David Parrish Start Presentation.
Economic Analysis and Management Todd Wagner, PhD.

Economic Analysis and Management Todd Wagner, PhD.
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)

A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.

Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
COST–EFFECTIVENESS ANALYSIS AND COST-UTILITY ANALYSIS

COST–EFFECTIVENESS ANALYSIS AND COST-UTILITY ANALYSIS
1 Civil Systems Planning Benefit/Cost Analysis Scott Matthews Courses: 12-706 and 73-359 Lecture 17 - 11/5/2003.

1 Civil Systems Planning Benefit/Cost Analysis Scott Matthews Courses: and Lecture /5/2003.
AGEC 608 Lecture 17, p. 1 AGEC 608: Lecture 17 Objective: Review the main aspects of cost- effectiveness analysis (CEA) and cost-utility analysis (CUA).

AGEC 608 Lecture 17, p. 1 AGEC 608: Lecture 17 Objective: Review the main aspects of cost- effectiveness analysis (CEA) and cost-utility analysis (CUA).
The Benefits of Risk Factor Prevention in Americans Aged 51 Years and Older Dana P. Goldman, Federico Girosi et al. American Journal of Public Health November.

The Benefits of Risk Factor Prevention in Americans Aged 51 Years and Older Dana P. Goldman, Federico Girosi et al. American Journal of Public Health November.
Economics and Health Thomas Songer, PhD South Asian Cardiovascular Research Methodology Workshop.

Economics and Health Thomas Songer, PhD South Asian Cardiovascular Research Methodology Workshop.
Chapter 4: Economic Efficiency and Cost Benefit Analysis 1.Economic Efficiency 2.Cost Benefit Analysis.

Chapter 4: Economic Efficiency and Cost Benefit Analysis 1.Economic Efficiency 2.Cost Benefit Analysis.
Do we need economics in medicine?. Edmund Burke, 1790 dcist.com/2007/12/10/revisiting_edmu.php “…the age of chivalry is gone. That of sophisters, economists,

Do we need economics in medicine?. Edmund Burke, 1790 dcist.com/2007/12/10/revisiting_edmu.php “…the age of chivalry is gone. That of sophisters, economists,
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.

Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.

Similar presentations

Ads by Google